Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Return on Equity (2016 - 2025)

Aptevo Therapeutics' Return on Equity history spans 10 years, with the latest figure at 1.7% for Q3 2025.

  • For Q3 2025, Return on Equity fell 176.0% year-over-year to 1.7%; the TTM value through Sep 2025 reached 1.7%, down 176.0%, while the annual FY2023 figure was 0.08%, 2.0% down from the prior year.
  • Return on Equity for Q3 2025 was 1.7% at Aptevo Therapeutics, up from 5.03% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.22% in Q4 2021 and bottomed at 5.03% in Q2 2025.
  • The 5-year median for Return on Equity is 0.05% (2022), against an average of 0.75%.
  • The largest annual shift saw Return on Equity soared 137bps in 2022 before it crashed -509bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.22% in 2021, then plummeted by -73bps to 0.06% in 2022, then skyrocketed by 53bps to 0.09% in 2023, then dropped by -28bps to 0.07% in 2024, then plummeted by -2675bps to 1.7% in 2025.
  • Per Business Quant, the three most recent readings for APVO's Return on Equity are 1.7% (Q3 2025), 5.03% (Q2 2025), and 3.95% (Q1 2025).